An observational study in Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), sponsored by Johannes Gutenberg University Mainz. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-17.
Sponsored by Johannes Gutenberg University Mainz · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Venous Thromboembolism with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Venous Thromboembolism · Germany.
Among the 61 studies in Venous Thromboembolism with a site in Germany, this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 2 that started in 2013, is one of 25 observational ones, and was the 35th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →4 of the 61 studies in Venous Thromboembolism with a site in Germany are open now. Recruiting first, the newest first:
University of Aarhus · Sites in Germany, Denmark
Ages 18+ · Healthy volunteers
Inari Medical · Sites in Germany, United States, Austria and 3 more countries
Ages 18+
Manuel Monreal · Sites in Germany, United States, Argentina and 26 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 27 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 700 across 283 observational studies indexed under Venous Thromboembolism.
Median enrollment 1,060 across the 36 interventional studies, 2,318 across the 25 observational. Of the 55 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 61 have an industry lead sponsor. The 10 most frequent:
Johannes Gutenberg University Mainz is the lead sponsor of 156 studies on the registry; 20 are open to participants now.
Johannes Gutenberg University Mainz has 2 studies filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
2 of the studies in Venous Thromboembolism with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02832245Manuel MonrealComputerized Registry of Patients With Venous Thromboembolism (RIETE) | 2026-12 |
| NCT06731673University of AarhusHeat Shock Protein 47 in Thrombosis | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 61 studies in Venous Thromboembolism with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed.
VTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE).
The standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.
Individuals either with clinically suspected or incident diagnosis of VTE
Inclusion Criteria:
Clinical condition:
Mortality
Overall mortality, consisting of: * PE-related death * All other causes of death
Time frame: Baseline
Symptomatic venous thromboembolism
Composed by: * PE-related death * Development or recurrence of nonfatal PE * Development or recurrence of DVT
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Hemodynamic instability
Defined as at least one of the following: * Cardiopulmonary resuscitation (CPR) or defibrillation * Cardiogenic shock or need of catecholamine administration * Systolic blood pressure \< 90mm Hg, or a pressure drop by more than 40mm Hg for \>15 min
Time frame: Baseline
Use of mechanical ventilation
Time frame: Baseline
Admission to Intensive Care Unit (ICU)
Time frame: Baseline
Recurrence of acute PE
Time frame: Baseline
Cardiac dysfunction or heart failure
Time frame: Baseline
Pneumonia
Time frame: Baseline
Symptomatic and/or asymptomatic DVT
Time frame: Baseline
Major bleeding
Time frame: Baseline
Clinically relevant non-major bleedings
Time frame: Baseline
Diagnostic of a previously unknown malignancy
Time frame: Baseline
Length of hospitalization
Time frame: Baseline
Implantation of vena cava filter
Time frame: Baseline
Thrombolytic treatment
Time frame: Baseline
Interventional treatment
Time frame: Baseline
Surgery
Time frame: Baseline
Overall mortality
Time frame: Assessment at month 3/6 and 12; year 2-6 (Active follow-up)
PE-related death
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Development or recurrence of clinical symptomatic PE/DVT
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Asymptomatic DVT
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Chronic venous insufficiency (CVI)
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Post-thrombotic Syndrome (PTS)
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Development of cardiac dysfunction or heart failure
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Development of pulmonary hypertension
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Respiratory dysfunction
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Major bleeding
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Clinically relevant non-major bleedings
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Diagnostic of a previously unknown malignancy
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Net clinical outcome (NCO)
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
O2 home treatment
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Pulmonary vasoactive drugs
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Development of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Hospitalization
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Length of stay in Hospital due to VTE
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Major adverse cardiac and cerebrovascular event (MACCE)
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Cardiovascular event
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Cerebrovascular event
Time frame: Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)
Started Apr 2013 (actual). Primary completion is estimated for Jul 2030, 207 months after the start.
Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 207 months is above that.
Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johannes Gutenberg University Mainz →